Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shawn C Black

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Current Opinion in Investigational Drugs (London, England : 2000)|May 12, 2004
Cannabinoid receptor antagonists and obesityShawn C Black
Journal of Pharmacological and Toxicological Methods|December 3, 2002
Validation of a high-resolution X-ray computed tomography system to measure murine adipose tissue depot mass in situ and longitudinallyAudrey L Hildebrandt, Dawn M Kelly-Sullivan, Shawn C Black
European Journal of Pharmacology|February 20, 2003
Antiobesity effects of chronic cannabinoid CB1 receptor antagonist treatment in diet-induced obese miceAudrey L Hildebrandt, Dawn M Kelly-Sullivan, Shawn C Black
Plos One|August 8, 2012
Beneficial metabolic effects of CB1R anti-sense oligonucleotide treatment in diet-induced obese AKR/J miceYuting Tang, George Ho, Yaxin Li, et al.
The Journal of Clinical Investigation|July 5, 2003
Severe diabetes, age-dependent loss of adipose tissue, and mild growth deficiency in mice lacking Akt2/PKB betaRobert S Garofalo, Stephen J Orena, Kristina Rafidi, et al.
Journal of Medicinal Chemistry|December 24, 2008
Discovery of 1-[9-(4-chlorophenyl)-8-(2-chlorophenyl)-9H-purin-6-yl]-4-ethylaminopiperidine-4-carboxylic acid amide hydrochloride (CP-945,598), a novel, potent, and selective cannabinoid type 1 receptor antagonistDavid A Griffith, John R Hadcock, Shawn C Black, et al.
American Journal of Physiology. Endocrinology and Metabolism|August 30, 2008
Pharmacological characterization of a small molecule inhibitor of c-Jun kinaseHelen Cho, Shawn C Black, David Looper, et al.
Biochemical and Biophysical Research Communications|March 10, 2010
In vitro and in vivo pharmacology of CP-945,598, a potent and selective cannabinoid CB(1) receptor antagonist for the management of obesityJohn R Hadcock, David A Griffith, Phillip A Iredale, et al.
Journal of Medicinal Chemistry|April 9, 2009
Discovery of 2-(2-chlorophenyl)-3-(4-chlorophenyl)-7-(2,2-difluoropropyl)-6,7-dihydro-2H-pyrazolo[3,4-f][1,4]oxazepin-8(5H)-one (PF-514273), a novel, bicyclic lactam-based cannabinoid-1 receptor antagonist for the treatment of obesityRobert L Dow, Philip A Carpino, John R Hadcock, et al.
BMC Pharmacology|August 18, 2010
Quantitative in vitro and in vivo pharmacological profile of CE-178253, a potent and selective cannabinoid type 1 (CB1) receptor antagonistJohn R Hadcock, Philip A Carpino, Philip A Iredale, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Current Opinion in Investigational Drugs (London, England : 2000)|May 12, 2004
Cannabinoid receptor antagonists and obesityShawn C Black
Journal of Pharmacological and Toxicological Methods|December 3, 2002
Validation of a high-resolution X-ray computed tomography system to measure murine adipose tissue depot mass in situ and longitudinallyAudrey L Hildebrandt, Dawn M Kelly-Sullivan, Shawn C Black
European Journal of Pharmacology|February 20, 2003
Antiobesity effects of chronic cannabinoid CB1 receptor antagonist treatment in diet-induced obese miceAudrey L Hildebrandt, Dawn M Kelly-Sullivan, Shawn C Black
Plos One|August 8, 2012
Beneficial metabolic effects of CB1R anti-sense oligonucleotide treatment in diet-induced obese AKR/J miceYuting Tang, George Ho, Yaxin Li, et al.
The Journal of Clinical Investigation|July 5, 2003
Severe diabetes, age-dependent loss of adipose tissue, and mild growth deficiency in mice lacking Akt2/PKB betaRobert S Garofalo, Stephen J Orena, Kristina Rafidi, et al.
Journal of Medicinal Chemistry|December 24, 2008
Discovery of 1-[9-(4-chlorophenyl)-8-(2-chlorophenyl)-9H-purin-6-yl]-4-ethylaminopiperidine-4-carboxylic acid amide hydrochloride (CP-945,598), a novel, potent, and selective cannabinoid type 1 receptor antagonistDavid A Griffith, John R Hadcock, Shawn C Black, et al.
American Journal of Physiology. Endocrinology and Metabolism|August 30, 2008
Pharmacological characterization of a small molecule inhibitor of c-Jun kinaseHelen Cho, Shawn C Black, David Looper, et al.
Biochemical and Biophysical Research Communications|March 10, 2010
In vitro and in vivo pharmacology of CP-945,598, a potent and selective cannabinoid CB(1) receptor antagonist for the management of obesityJohn R Hadcock, David A Griffith, Phillip A Iredale, et al.
Journal of Medicinal Chemistry|April 9, 2009
Discovery of 2-(2-chlorophenyl)-3-(4-chlorophenyl)-7-(2,2-difluoropropyl)-6,7-dihydro-2H-pyrazolo[3,4-f][1,4]oxazepin-8(5H)-one (PF-514273), a novel, bicyclic lactam-based cannabinoid-1 receptor antagonist for the treatment of obesityRobert L Dow, Philip A Carpino, John R Hadcock, et al.
BMC Pharmacology|August 18, 2010
Quantitative in vitro and in vivo pharmacological profile of CE-178253, a potent and selective cannabinoid type 1 (CB1) receptor antagonistJohn R Hadcock, Philip A Carpino, Philip A Iredale, et al.
Pageof 2